# DESCRIPTION

## FIELD OF THE INVENTION

- introduce immune-checkpoint inhibitors for blood-borne cancers

## BACKGROUND OF THE INVENTION

- motivate immune-checkpoint blockade
- describe immune-checkpoint pathways
- explain T cell activation
- discuss B7 family members
- describe TNF family members
- explain cytokine signals
- discuss tumor immune resistance
- introduce cancer immunotherapy

## SUMMARY OF THE INVENTION

- introduce immunomodulating compounds
- describe pharmaceutical composition with CAR T cells
- describe pharmaceutical composition with antibody construct
- motivate need for new immune-checkpoints
- introduce CD112, CD155, TIGIT, Galectin-9, and TIM-3
- describe inhibitors against CD112, CD155, TIGIT, Galectin-9, and TIM-3
- describe combination with CAR T cells
- describe combination with antibody construct
- describe inhibitor against CD112
- describe inhibitor against CD155
- describe inhibitor against TIGIT
- describe inhibitor against Galectin-9
- describe inhibitor against TIM-3
- describe antibody construct
- describe CAR T cell
- describe immunostimulant
- describe iRNA
- describe CRISPR/cas9 technique
- describe modulation of intracellular signaling
- describe pharmaceutical composition

## DETAILED DESCRIPTION

- disclaim prior art
- introduce immune-checkpoint inhibitors
- motivate treatment of blood-borne cancers
- describe CD112 and CD155 as targets
- describe Galectin-9 and TIM-3 as targets
- summarize negative prognostic impact of PVR and PVRL2
- describe blockage of PVR, PVRL2, or TIGIT
- summarize contradictory data on Galectin-9 and TIM-3
- describe blockage of Galectin-9 and TIM-3
- summarize protein expression of PVR and PVRL2
- compare protein density on AML cell lines and PBMCs
- describe protein expression on primary blasts of AML patients
- summarize immunosuppressive signal of PVR and PVRL2
- summarize immunosuppressive signal of Galectin-9 and TIM-3
- define inhibit or inhibiting
- define blood-borne cancer
- describe potential treatment of solid tumors
- define acute myeloid leukemia
- define refractory and relapsed AML
- define immune-checkpoint inhibitor
- modulate intracellular signaling
- treat blood-borne cancer
- inhibit interaction between immune-checkpoint ligand and receptor
- define antibody construct
- describe antibody structure and function
- inhibit immunoinhibitory interaction
- bind to immune-checkpoint ligands or receptors
- define antibody fragments
- describe production of antibody constructs
- produce single chain antibodies
- use transgenic animals to express humanized antibodies
- prepare monoclonal antibodies
- use surface plasmon resonance to increase efficiency of phage antibodies
- define antibody variants
- describe humanized variants of non-human antibodies
- describe affinity matured antibodies
- describe antibody mutants with altered effector function
- define antigen-binding domain
- describe Fab fragment
- describe F(ab′)2 fragment
- describe Fd fragment
- describe Fv fragment
- describe dAb fragment
- describe single chain Fv (scFv)
- define bispecific single chain antibody construct
- describe peptide linker
- define characteristics of peptide linker
- describe genetic engineering of bispecific single chain constructs
- express bispecific single chain constructs in mammalian cells or bacteria
- describe preferred peptide linkers
- describe single amino acid peptide linker
- define monoclonal antibody
- describe characteristics of monoclonal antibodies
- introduce human antibody
- describe human antibody features
- define antibody variants
- provide examples of antibody variants
- introduce in vitro generated antibody
- describe VH and VL domains
- explain framework regions and CDRs
- define variable and hypervariable regions
- describe CDR boundaries and lengths
- introduce isolated proteins
- describe isolated protein characteristics
- disclose experimental results
- introduce CD112, CD155, TIGIT, Galectin-9, and TIM-3 inhibitors
- describe protein and non-protein compounds as inhibitors
- introduce soluble proteins as inhibitors
- describe preparation of soluble proteins
- introduce polypeptide fragments as mutual antagonists
- describe design of antagonists by computer
- introduce small molecule inhibitors
- describe characteristics of small molecules
- introduce small molecule drugs for blood-borne cancers
- describe routes for delivering small molecule drugs
- describe inhibitor of CD112, CD155, TIGIT, Galectin-9, and/or TIM-3
- reduce expression of CD112, CD155, TIGIT, Galectin-9, and/or TIM-3
- define "reduce expression"
- describe nucleotides capable of reducing expression
- describe RNAi
- describe synthesis and delivery of RNAi
- describe "knock out" of CD112, CD155, TIGIT, Galectin-9, and/or TIM-3
- define "knock out"
- describe CRISPR/Cas9 technique
- describe other knockout techniques
- describe CAR T cell
- describe CAR T cell recognizing CD33
- describe addition of CAR T cells to inhibitors
- describe CAR T cell having binding domain targeting CD33, CD19, or Flt3
- describe bispecific T cell engagers
- describe BiTE antibody constructs
- describe different formats of antibody constructs
- describe binding domains within T cell engaging molecule
- describe Fd fragments
- describe Fab fragment
- describe F(ab′)2 fragment
- describe Fv fragment
- describe dAb fragment
- describe single chain Fv
- describe in vitro killing assays
- describe therapeutic effect of PVR and PVRL2 blockage
- describe inhibitors comprising antibody construct
- describe antibody construct having CD3 binding domain and CD33 binding domain
- describe antibody construct having CD3 binding domain and CD19 binding domain
- describe antibody construct having CD3 binding domain and Flt3 binding domain
- describe multifunctional compound
- describe bispecific antibody constructs targeting CD33, CD19, or Flt3
- define "specifically interacting"
- describe production of targeting compound in bacteria
- describe purification of targeting compound
- describe screening method for inhibitor
- define treatment
- describe term "treat"
- define therapeutically effective amount
- describe administration methods
- define subject
- describe pharmaceutical formulation composition
- describe thickening agents
- describe solid carrier
- describe further AML treatment
- describe hematopoietic stem cell transplantation
- describe chemotherapeutic treatment
- describe radiation therapy
- describe CNS treatment
- describe immunopotentiating activity
- describe CAR T cells
- describe antibody construct
- describe pharmaceutical composition
- describe formulation materials
- describe administration methods
- describe uninterrupted administration
- describe pharmaceutical carriers
- describe carbohydrates
- describe buffer solutions
- describe amino acids
- describe surfactants
- describe detergents
- describe polyethers
- describe buffer systems
- describe dose determination
- describe dosage regimen
- describe preparations for parenteral administration
- describe sterile aqueous solutions
- describe non-aqueous solvents
- describe parenteral vehicles
- describe intravenous vehicles
- describe preservatives
- describe proteinaceous carriers
- describe biologically active agents
- describe co-therapy
- describe biological activity
- describe efficacy
- describe in vivo efficacy
- describe pharmacokinetic properties
- describe half-life
- describe volume of distribution
- describe hepatic first-pass metabolism
- describe degree of blood serum binding
- describe toxicity
- define safety
- evaluate safety
- define effective dose
- define therapeutically effective dose
- define effective and non-toxic dose
- determine effective and non-toxic dose
- describe pharmaceutical composition administration
- describe pharmaceutical composition formulation
- describe pharmaceutical composition materials
- describe pharmaceutical composition preparation
- describe pharmaceutical composition storage
- describe disease treatment
- describe disease prevention
- describe pharmaceutical composition use
- describe inhibitor and CAR T cell combination
- describe synergistic effect
- describe redirected lysis
- describe formulations
- describe pharmaceutical composition components
- describe buffers
- describe preservatives
- describe antioxidants
- describe stabilizers
- describe tonicity enhancers
- describe delivery vehicles
- describe excipients
- describe pharmaceutical adjuvants
- describe optimal pharmaceutical composition
- describe primary vehicle or carrier
- describe pharmaceutical composition preparation
- describe lyophilization
- describe reconstitution
- describe sustained-release formulations
- describe controlled-delivery formulations
- describe liposome carriers
- describe bio-erodible microparticles
- describe porous beads
- describe depot injections
- describe sterilization
- describe salts
- describe Hofmeister series
- describe kosmotropes
- describe chaotropes
- describe pharmaceutical composition administration

### Examples

- introduce examples of specific embodiments
- analyze patient samples for immune checkpoint molecules
- correlate expression with patient demographics and clinical survival data
- identify independent prognostic markers
- study therapeutic effect of PVR and PVRL2 blockade
- perform in vitro killing assays
- confirm specificity of approach using CRISPR/Cas-9
- exclude effects caused by antibody dependent cellular cytotoxicity
- describe prognostic impact of PVR, PVRL2 and Galectin-9 in AML
- analyze mRNA expression of PVR, PVRL2 and Galectin-9
- correlate gene expression with patient demographics and clinical survival data
- describe protein expression of PVR, PVRL2 and Galectin-9
- describe T-cell induced AML cell lysis

